万泰生物去年营收22.45亿元，获安哥拉、尼泊尔、泰国等国疫苗采购订单

Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024, with revenue decreasing by 59.25% to 2.245 billion yuan and net profit dropping by 91.49% to 106 million yuan [1]. Industry Analysis - The vaccine sector experienced a substantial revenue decline of 84.69%, totaling 606 million yuan, while the in vitro diagnostics (IVD) business saw a revenue increase of 4.91%, reaching 1.609 billion yuan [2]. - In the IVD sector, the company has completed the layout of high, medium, and low throughput instruments, including three fully automated chemiluminescence immunoassay analyzers and 115 corresponding reagents, addressing various clinical testing needs [2]. - The company is advancing a high-throughput fully automated biochemical analyzer, WanBC2800, to enhance its product line and meet diverse user demands [2]. - A new nucleic acid detection product based on microfluidic technology is under development, promising rapid testing processes and improved efficiency [2]. - The IVD segment achieved nearly double-digit growth despite policy impacts, with notable increases in reagent consumables such as chemiluminescence reagents (up 19%) and tuberculosis detection reagents (up 50%) [3]. Product Development - The company is focusing on vaccine development, particularly the nine-valent HPV vaccine, which is progressing well through clinical trials and is on track for commercialization [5][6]. - The company is also advancing several other vaccine candidates, including a 20-valent pneumonia conjugate vaccine and a recombinant herpes zoster vaccine, with various stages of clinical trials and regulatory submissions ongoing [6]. International Market Expansion - The company is actively promoting its bivalent HPV vaccine, Cecolin®, for inclusion in national immunization programs across multiple countries, including Thailand and Nicaragua [8]. - New markets have been added, with countries like Angola, Tunisia, Burundi, and Pakistan incorporating the vaccine into their immunization plans, and several procurement orders have been secured [8].